Chitraporn Karnasuta

Summary

Affiliation: Armed Forces Research Institute of Medical Sciences
Country: Thailand

Publications

  1. ncbi A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost
    Prasert Thongcharoen
    Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand
    J Acquir Immune Defic Syndr 46:48-55. 2007
  2. ncbi Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand
    Chitraporn Karnasuta
    Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
    Vaccine 23:2522-9. 2005
  3. ncbi Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults
    Sorachai Nitayaphan
    Royal Thai Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
    J Infect Dis 190:702-6. 2004
  4. ncbi HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E
    Robert Paris
    Department of Retrovirology and Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
    Vaccine 30:832-6. 2012
  5. ncbi Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV phase I/II prime boost vaccine trial in Thail
    Wannee Kantakamalakul
    Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
    AIDS Res Hum Retroviruses 20:642-4. 2004
  6. ncbi Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans
    Michael A Eller
    Makerere University Walter Reed Project, Kampala, Uganda
    Vaccine 25:7737-42. 2007

Collaborators

Detail Information

Publications6

  1. ncbi A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost
    Prasert Thongcharoen
    Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand
    J Acquir Immune Defic Syndr 46:48-55. 2007
    ..A prime-boost HIV-1 vaccine trial assessing safety and immunogenicity was conducted in Thailand as part of an evaluation of candidate regimens for a phase 3 efficacy trial...
  2. ncbi Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand
    Chitraporn Karnasuta
    Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
    Vaccine 23:2522-9. 2005
    ..The results demonstrate that this HIV vaccine is a potent inducer of ADCC activity and may be an additional protection of this prime-boost vaccine in preventing HIV disease...
  3. ncbi Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults
    Sorachai Nitayaphan
    Royal Thai Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
    J Infect Dis 190:702-6. 2004
    ..This vaccine combination was well tolerated and was immunogenic, meeting milestones for advancement to phase 3 evaluation...
  4. ncbi HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E
    Robert Paris
    Department of Retrovirology and Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
    Vaccine 30:832-6. 2012
    ..009). These data suggest that the lack of response to a vaccine designed to induce clade-specific NAb to HIV-1 is associated with the presence of certain HLA class II alleles and heterodimers in some Southeast Asians...
  5. ncbi Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV phase I/II prime boost vaccine trial in Thail
    Wannee Kantakamalakul
    Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
    AIDS Res Hum Retroviruses 20:642-4. 2004
    ..These results imply that extension of the IVS period may increase the sensitivity of the CRA when measuring HIV-specific CTL in ALVAC-HIV prime-boost recipients without compromising specificity...
  6. ncbi Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans
    Michael A Eller
    Makerere University Walter Reed Project, Kampala, Uganda
    Vaccine 25:7737-42. 2007
    ....